Originalarbeiten
T. Hendrayana, V. Kurth, L. Krolop, P. Kenny, R.A. Hilger, I.G.H. Schmidt-Wolf, Y.D. Ko, U. Jaehde
Variability in fluorouracil exposure during continuous intravenous infusion
Jahrestagung der Central European Society of Anticancer
Drug Research (CESAR) 2011, Greifswald, 16.-18. Juni 2011
Publiziert als Extended Abstract Int. J. Clin. Pharmacol. Ther. 50 (1): 82-84, 2012
S. Simons, S. Ringsdorf, M. Braun, U.J. Mey, P.F. Schwindt, Y.D. Ko, I. Schmidt-Wolf, W. Kuhn, U. Jaehde.
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Support. Care Cancer. 19 (7): 1009-1018, 2011
N. Döhler, L. Krolop, S. Ringsdorf, K. Meier, Y.D. Ko, W. Kuhn, O. Schwalbe, U. Jaehde
Task allocation in cancer medication management - integrating the pharmacist.
Patient. Educ. Couns. 83 (3): 367-374, 2011
I. Buss, D. Garmann, M. Galanski, G. Weber, G.V. Kalayda, B.K. Keppler, U. Jaehde
Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?
J. Inorg. Biochem. 105 (5): 709-717, 2011
F. Kanefendt, A. Lindauer, M. Kinzig, D. Strumberg, M.E. Scheulen, K. Mross, R. Fischer, B. Moritz, F. Sörgel, U. Jaehde
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients
Jahrestagung der Central European Society of Anticancer
Drug Research (CESAR) 2010, St. Gallen, 01.-03. Juli 2010
Publiziert als Extended Abstract Int. J. Clin. Pharmacol. Ther. 49 (1): 88-90, 2011
K. Mross, M. Büchert, U. Fasol, U. Jaehde, F. Kanefendt, D. Strumberg, J. Arends, J. Hense, B. Moritz, R. Fischer, M.E. Scheulen
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment – a study of the CESAR central european society for anticancer drug research – EWIV
Jahrestagung der Central European Society of Anticancer
Drug Research (CESAR) 2010, St. Gallen, 01.-03. Juli 2010
Publiziert als Extended Abstract Int. J. Clin. Pharmacol. Ther. 49 (1): 96-98, 2011
S. Retlich, V. Duval, A. Ring, A. Staab, S. Hüttner, A. Jungnik, U. Jaehde, K.A. Dugi, U. Graefe-Mody
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Clin. Pharmacokinet. 49 (12): 829-840, 2010
K. Abduljalil, D. Frank, A. Gaedigk, T. Klaassen, D. Tomalik-Scharte, A. Jetter, U. Jaehde, J. Kirchheiner, U. Fuhr
Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.
Clin. Pharmacol. Ther. 88 (5): 643-651, 2010
S. Retlich, V. Duval, U. Graefe-Mody, U. Jaehde, A. Staab
Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.
J. Clin. Pharmacol. 50 (8): 873-885, 2010
V. Schneider, G.V. Kalayda, M.L. Krieger, G. Bendas, U. Jaehde
Intracellular
ATP depletion leads to reduced platinum accumulation in ovarian cancer
cells.
Jahrestagung der Central European Society of Anticancer
Drug Research (CESAR) 2009, Heidelberg, 29.-31. Oktober 2009
Publiziert
als Extended Abstract Int. J. Clin. Pharmacol. Ther. 48: 456-458, 2010
C.
Mohn, G.V. Kalayda, H.-G. Häcker, M. Gütschow, S. Metzger, U. Jaehde.
Contribution
of glutathione and MRP-mediated efflux to intracellular oxaliplatin
accumulation.
Jahrestagung der Central European Society of
Anticancer Drug Research (CESAR) 2009, Heidelberg, 29.-31. Oktober 2009
Publiziert
als Extended Abstract Int. J. Clin. Pharmacol. Ther. 48: 445-447, 2010
M.L. Krieger, A. Konold, M. Wiese, U. Jaehde, G. Bendas
Targeted doxorubicin-liposomes as a tool to circumvent P-gp-mediated resistance in ovarian carcinoma cells.
Jahrestagung der Central European Society of
Anticancer Drug Research (CESAR) 2009, Heidelberg, 29.-31. Oktober 2009
Publiziert
als Extended Abstract Int. J. Clin. Pharmacol. Ther. 48 (7): 442-444, 2010
A. Lindauer, P. Di Gion, F. Kanefendt, D. Tomalik-Scharte, M. Kinzig, M. Rodamer, F. Dodos, F. Sörgel, U. Fuhr, U. Jaehde
Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.
Clin. Pharmacol. Ther. 87.(5):.601-608, 2010
A. Lindauer, C. Eickhoff, C. Kloft, U. Jaehde
Population pharmacokinetics of high-dose carboplatin in children and adults.
Ther. Drug. Monit. 32 (2): 159-168, 2010
M.L. Krieger, N. Eckstein, V. Schneider, M. Koch, H.D. Royer, U. Jaehde, G. Bendas
Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
Int. J. Pharm. 389 (1-2): 10-17, 2010
A. Rotte, D. Garmann, I. Buss, U. Jaehde
Effect of extracellular ATP on cisplatin-induced cytotoxicity in human ovarian carcinoma cells.
Chemotherapy. 56 (1): 1-8, 2010
E.L. Swennen, V. Ummels, I. Buss, U. Jaehde, A. Bast, P.C. Dagnelie
ATP sensitizes H460 lung carcinoma cells to cisplatin-induced apoptosis.
Chem. Biol. Interact. 184 (3): 338-345, 2010
C.B. Landersdorfer, C.M. Kirkpatrick, M. Kinzig, J.B. Bulitta, U. Holzgrabe, U. Jaehde, A. Reiter, K.G. Naber, M. Rodamer, F. Sörgel
Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.
Br. J. Clin. Pharmacol. 69 (2): 167-78, 2010
P. Marqués-Gallego, S. Contaldi, H. den Dulk, M. Monari, J. Brouwer, U. Jaehde, G.V. Kalayda, J. Reedijk
Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand.
J. Inorg. Biochem. 103 (12): 1602-1608, 2009
S. Retlich, B. Withopf, A. Greischel, A. Staab, U. Jaehde, H. Fuchs
Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
Biopharm. Drug Dispos. 30 (8): 422-436, 2009
P. Milla, M. Airoldi, G. Weber, A. Drescher, U. Jaehde, L. Cattel.
Administration
of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal
cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation,
and neurotoxicity.
Anticancer Drugs. 20 (5): 396-402, 2009
P. Marqués-Gallego, G.V. Kalayda, U. Jaehde, H. Dulk, J. Brouwer, J. Reedijk
Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands.
J. Inorg. Biochem. 103 (5): 791-796, 2009
F. Lentz, A. Drescher, A. Lindauer, M. Henke, R.A. Hilger, C.G. Hartinger, M.E. Scheulen, C. Dittrich, B.K. Keppler, U. Jaehde, Central European Society for Anticancer Drug Research-EWIV.
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
Anticancer Drugs. 20 (2): 97-103, 2009
M.M. Henke, H. Richly, A. Drescher, M. Grubert, D. Alex, D. Thyssen, U. Jaehde, M.E. Scheulen, R.A. Hilger.
Pharmacokinetic
study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate
(III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid
tumors.
Int. J. Clin. Pharmacol. Ther. 47 (1): 58-60, 2009
I. Buss, G.V. Kalayda, P. Marques-Gallego, J. Reedijk, U. Jaehde
Influence of the hOCT2 inhibitor cimetidine on the cellular accumulation and cytotoxicity of oxaliplatin.
Int. J. Clin. Pharmacol. Ther. 47 (1): 51-54, 2009
S. Vezmar, P. Schüsseler, A. Becker, U. Bode, U. Jaehde
Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity.
Pediatr. Blood Cancer. 52 (1): 26-32, 2009
D. Garmann, A. Warnecke, G.V. Kalayda, F. Kratz, U. Jaehde.
Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
J. Control. Release. 131: 100-106, 2008
G.V. Kalayda, C.H. Wagner, I. Buss, J. Reedijk, U. Jaehde.
Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
BMC Cancer. 8 (1): 175, 2008
A. Lindauer, T. Siepmann , R. Oertel, A. Jung, T. Ziemssen, U. Jaehde, W. Kirch, M. Siepmann.
Pharmacokinetic/Pharmacodynamic Modeling of Venlafaxine: Pupillary Light Reflex as Test-system for Noradrenergic Effects.
Clin. Pharmacokinet. 47 (11): 721-731, 2008
A.C. Pieck, A. Drescher, K.G. Wiesmann, J. Messerschmidt, G. Weber, D. Strumberg, R.A. Hilger, M.E. Scheulen, U. Jaehde.
Oxaliplatin-DNA adduct formation in white blood cells of cancer patients.
Br. J. Cancer. 98: 1959-1965, 2008
T. Klaassen, A. Jetter, D. Tomalik-Scharte, D. Kasel, J. Kirchheiner, U. Jaehde, U. Fuhr.
Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.
Eur. J. Clin. Pharmacol. 64: 387-398, 2008
M. Baur, A. Drescher, M. Gneist, C. Dittrich, U. Jaehde.
Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Cancer Chemother. Pharmacol. 61: 97-104, 2008
N. Eckstein, K. Servan, L. Girard, D. Cai, G. von Jonquieres, U. Jaehde, M.U. Kassack, A.F. Gazdar, J.D. Minna, H.D. Royer.
Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.
J. Biol. Chem. 283: 739-750, 2008
A. Becker, S. Vezmar, M. Linnebank, H. Pels, U. Bode, U. Schlegel, U. Jaehde.
Marked elevation of homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate.
Int. J. Clin. Pharmacol. Ther. 45: 504-515, 2007
S. Wilde, A. Jetter, S. Rietbrock, D. Kasel, A. Engert, A. Josting, B. Klimm, G. Hempel, S. Reif, U. Jaehde, U. Merkel, D. Busse, M. Schwab, V. Diehl, U. Fuhr.
Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.
Clin. Pharmacokinet. 46: 319-333, 2007
J. Zisowsky, S. Koegel, S. Leyers, K. Devarakonda, M.U. Kassack, M. Osmak, U. Jaehde.
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.
Biochem. Pharmacol. 73: 298-307, 2007
M. Hunz, A. Jetter, M. Warm, E. Pantke, M. Tuscher, G. Hempel, U. Jaehde, M. Untch, C. Kurbacher, U. Fuhr.
Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
Clin. Pharmacol. Ther. 81: 659-668, 2007
D. Schreiber, S. Harlfinger, B.M. Nolden, C.W. Gerth, U. Jaehde, E. Schomig, J. Klosterkotter, A. Giuffrida, G. Astarita, D. Piomelli, M.F. Leweke.
Determination of anandamide and ohter fatty acyl ethanolamides in human serum by electrosspray tandem mass spectrometry.
Anal. Biochem. 361: 162-168, 2007
E.D. Greaves, M. Angeli-Greaves, U. Jaehde, A. Drescher, A. von Bohlen.
Rapid determination of platinum plasma concentrations of chemotherapy patients using total reflection X-ray fluorescence.
Spectrochim. Acta. B. 61: 1194-1200, 2006
C. Lanvers-Kaminsky, B. Krefeld, A.G. Dinnesen, D. Deuster, E. Seifert, G. Würthwein, U. Jaehde, A.C. Pieck, J. Boos.
Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Pediatr. Blood Cancer. 47: 183-193, 2006
G. Ciarimboli, T. Ludwig, D. Lang, H. Pavenstedt, H. Koepsell, H.J. Piechota, J. Haier, U. Jaehde, J. Zisowsky, E. Schlatter.
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2.
Am. J. Pathol. 167: 1477-1484, 2005
R.D. Hofheinz, D. Dittrich, M.A. Jakupec, A. Drescher, U. Jaehde, M. Gneist, N. Graf von Keyserlingk, B.K. Keppler, A. Hochhaus.
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - a CESAR study (Central European Society for Anticancer Drug Research - EWIV).
Int. J. Clin. Pharmacol. Ther. 43: 590-591, 2005
A. Rümelin, T. Humbert, O. Luhker, A. Drescher, U. Fauth.
Metabolic clearance of the antioxidant ascorbic acid in surgical patients.
J. Surg. Res. 129: 46-51, 2005
A. Rümelin, U. Jaehde, T. Kerz, W. Roth, M. Krämer, U. Fauth.
Early postoperpative substitution procedure of the antioxidant ascorbic acid.
J. Nutr. Biochem. 16: 104-108, 2005
A. Liekweg, M. Eckhardt, S.C. Malfair Taylor, E. Erdfelder, U. Jaehde.
Psychometric assessment and application of a questionnaire measuring patient satisfaction with information on cancer treatment.
Pharm. World Sci. 27: 96-103, 2005
M. Heim, M. Scharifi, J. Zisowsky, U. Jaehde, D. Voliotis, S. Seeber, D. Strumberg.
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Anticancer Drugs. 16: 129-136, 2005
D. Garmann, A. Warnecke, F. Kratz, U. Jaehde.
Reactivity of novel albumin-binding platinum complexes.
Int. J. Clin. Pharmacol. Ther. 42: 646-647, 2004
A. Brozovic, G. Fritz, M. Christmann, J. Zisowsky, U. Jaehde, M. Osmak, B. Kaina.
Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.
Int. J. Cancer 112: 974-985, 2004
U. Warnke, C. Rappel, H. Meier, C. Kloft, M. Galanski, C.G. Hartinger, B.K. Keppler, U. Jaehde.
Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5'-monophosphate O6-N7 chelation.
ChemBioChem 5: 1543-1549, 2004
A. Warnecke, I. Fichtner, D. Garmann, U. Jaehde, F. Kratz.
Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug Carboplatin designed as albumin-binding prodrugs.
Bioconjug. Chem. 15: 1349-1359, 2004
K. Grasmäder, P.L. Verwohlt, K.U. Kuhn, A. Dragicevic, O. von Widdern, A. Zobel, C. Hiemke, M. Rietschel, W. Maier, U. Jaehde, M.L. Rao.
Population pharmacokinetic analysis of mirtazapine.
Eur. J. Clin. Pharmacol. 60: 473-480, 2004
A. Junker, A. Kretzschmar, U. Böhm, A. Tannapfel, D. Langenbahn, A.C. Pieck, U. Jaehde.
Therapie eines Patienten mit Darmkrebs. Verstärkte Neurotoxizität nach Oxaliplatin und anschließender Entfernung der Lebermetastasen.
Med Monatsschr Pharm. 27: 349-352, 2004
G. Weber, J. Messerschmidt, A.C. Pieck, A.M. Junker, A. Wehmeier, U. Jaehde.
Ultratrace voltammetric determination of DNA-bound platinum in patients after administration of oxaliplatin.
Anal. Bioanal. Chem. 380: 54-58, 2004
C. Kloft, W. Siegert, U. Jaehde.
Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer.
Br. J. Cancer 89: 787-794, 2003
C. Sirisangtragul, G. Henke, G. Fleischhack, S. Reif, C. Kloft, U. Bode, U. Jaehde.
Cerebrospinal fluid pharmacokinetics after different dosage regimens of intraventricular etoposide.
Int. J. Clin. Pharmacol. Ther. 41: 606-607, 2003
J. Zisowsky, A. Becker, S. Weykam, M. Kassack, U. Jaehde.
Assessment of platinum sensitivity of human tumor cells.
Int. J. Clin. Pharmacol. Ther. 41: 612-613, 2003
K. Grasmäder, U. Jaehde, P.L. Lohmann, M.L. Rao.
Optimierung des TDM von Lithium durch computergestützte Dosisindividualisierung.
Psychopharmakotherapie 10: 15-18, 2003
A.M. Junker, A.C. Pieck, A. Wehmeier, U. Jaehde.
Interindividual differences in oxaliplatin pharmacokinetics.
Int. J. Clin. Pharmacol. Ther. 40: 569-570, 2002
S. Reif, A. Jetter, U. Fuhr, H. McLeod, D. Kingreen, W. Siegert, U. Jaehde.
Population pharmacokinetics of etoposide.
Int. J. Clin. Pharmacol. Ther. 40: 578-579, 2002
S. Vezmar, U. Bode, U. Jaehde.
Monitoring of methotrexate and reduced folates in the cerebrospinal fluid of cancer patients.
Int. J. Clin. Pharmacol. Ther. 40: 582-583, 2002
S. Wilde, A. Jetter, M. Zaigler, S. Rietbrock, H. Menzel, M. Sieber, H. Tesch, G. Hempel, D. Busse, M. Schwab, S. Reif, U. Jaehde, V. Diehl, U. Fuhr.
Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy.
Int. J. Clin. Pharmacol. Ther. 40: 586-588, 2002
S. Reif, M.C. Nicolson, D. Bisset, C. Kloft, U. Jaehde, H. McLeod.
Effect of grapefruit juice on etoposide bioavailability.
Eur. J. Clin. Pharmacol. 58: 491-494, 2002
A. Becker, E. Scheuch, U. Bode, U. Jaehde.
Simultaneous analysis of sulfur-containing excitatory amino acids using micellar electrokinetic chromatography with diode array and laser-induced fluorescence detection.
Electrophoresis 23: 2457-2464, 2002
C. Kloft, W. Siegert, J. Beyer, U. Jaehde.
Toxicity of high-dose carboplatin: Ultrafiltered and not total plasma pharmacokinetics is of clinical relevance.
J. Clin. Pharmacol. 42: 762-773, 2002
C. Schröder, S. Fisher, A.C. Pieck, A. Müller, U. Jaehde, H. Kirchner, A. Haverich, P. Macchirini.
Technique and results of hyperthermic (41°C) isolated lung perfusion with high doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis.
Eur. J. Cardiothorac. Surg. 22: 41-46, 2002
U. Warnke, J. Gysler, B. Hofte, U.R. Tjaden, J. van der Greef, C. Kloft, W. Schunack, U. Jaehde.
Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometry.
Electrophoresis 22: 97-103, 2001
G. Fleischhack, S. Reif, C. Hasan, U. Jaehde, S. Hettmer, U. Bode.
Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumors.
Br. J. Cancer 84: 1453-1459, 2001
S. Reif, D. Kingreen, C. Kloft, J. Grimm, W. Siegert, W. Schunack, U. Jaehde.
Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients.
Cancer Chemother. Pharmacol. 48: 134-140, 2001
C. Lorenz, C. Eickhoff, F. Baumann, J. Sehouli, R. Preiss, W. Schunack, U. Jaehde.
Does ondansetron affect the metabolism of cyclophosphamide?
Int. J. Clin. Pharmacol. Ther. 38: 143-144, 2000
S. Wilde, A. Jetter, H. Menzel, S. Rietbrock, M. Zaigler, M. Sieber, H. Tesch, G. Hempel, S. Reif, U. Jaehde, U. Merkel, S. Johnson, V. Diehl, U. Fuhr.
Population pharmacokinetics of drugs in the BEACOPP chemotherapy regimen used in HodgkinŽs disease.
Int. J. Clin. Pharmacol. Ther. 38: 147-149, 2000
S. Reif, J. Grimm, D. Kingreen, W. Siegert, W. Schunack, U. Jaehde.
Pharmacokinetics of etoposide following administration of high-dose etoposide and etoposide phosphate.
Int. J. Clin. Pharmacol. Ther. 38: 156-157, 2000
J. Gysler, W. Schunack, U. Jaehde.
Monitoring of chemotherapy-induced proteinuria using capillary zone electrophoresis.
J. Chromatogr. B 721: 207-216, 1999
C. Kloft, C. Eickhoff, K. Schulze-Forster, H.R. Maurer, W. Schunack, U. Jaehde.
Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA.
Pharm. Res. 16: 470-473, 1999
S. Stremetzne, M. Streit, E.D. Kreuser, W. Schunack, U. Jaehde.
Randomized pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer.
Pharm. World Sci. 21: 184-189, 1999
F. Baumann, C. Lorenz, U. Jaehde, R. Preiss.
Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry.
J. Chromatogr. B 729: 297-305, 1999
J. Gysler, M. Mazereeuw, B. Helk, M. Heitzmann, U. Jaehde, W. Schunack, U.R. Tjaden, J. van der Greef.
Utility of isotachophoresis-capillary zone electrophoresis, mass spectrometry and high-performance size-exclusion chromatography for monitoring of interleukin-6 dimer formation.
J. Chromatogr. A 841: 63-73, 1999
C. Kloft, H. Appelius, W. Siegert, W. Schunack, U. Jaehde.
Determination of platinum complexes with antitumor activity in clinical samples by a rapid flameless atomic absorption spectrometry assay.
Ther. Drug Monit. 21: 631-637, 1999
J. Gysler, U. Jaehde, W. Schunack.
Electromigration dispersion of isotachophoretic protein zones during capillary zone electrophoresis.
Fresenius J. Anal. Chem. 365: 398-403, 1999
